Medical Polyurethane Market Size & Share - Growth Analysis and Forecast 2026-2035

Medical Polyurethane Market - Regional Analysis

North America Market Insights

North America medical polyurethane market is anticipated to lead with a total share of 34.3% during the discussed timeframe. The region’s leadership is mainly propelled by highly sophisticated healthcare infrastructure and a strong emphasis on medical device innovation.  North America boasts an exceptionally high volume of minimally invasive surgeries, which directly accelerates the adoption of premium polyurethane-based catheters, tubing, and interventional cardiovascular devices. In February 2023, the U.S. Food & Drug Administration (FDA) reported that the LimFlow™ System is an approved device designed to treat chronic limb-threatening ischemia by creating an artery-to-vein connection to restore blood flow to the foot in patients unsuitable for surgical bypass. This system uses specialized catheters, a valvulotome, and polymer-covered nitinol stents to establish a new blood flow pathway, bypassing blocked arteries, thus denoting a sustained demand for medical polyurethanes.

The prominent medical device manufacturing sector and extensive domestic healthcare expenditures are driving growth of the U.S. medical polyurethane market. The country’s market progression is sustained by continued R&D efforts, which are centered on advanced, bio-stable polymers that mitigate infection risks and enhance patient safety during prolonged clinical use.  In December 2023, Bactiguard and BD expanded their partnership through an exclusive global licensing agreement (excluding China) for Bactiguard-coated Foley catheters to improve availability and continuity of advanced catheter technology. This collaboration supports Bactiguard’s transition toward a licensing-focused business model while allowing BD to provide coated Foley catheters. Hence, such collaborations will benefit the country’s market by improving access to advanced infection-reducing Foley catheter technologies.

In Canada, the medical polyurethane market is utterly backed by a strong emphasis on improving patient outcomes. The country’s growing focus on home-based healthcare and outpatient services significantly boosts the domestic demand for durable, flexible polyurethane consumables, particularly. Canada’s medical device developers proactively collaborate with public research universities to develop and distribute specialized, high-purity polymer formulations that optimize biocompatibility. In June 2025, Lubrizol expanded its partnership with IMCD with a prime focus on strengthening the distribution of its medical-grade TPU solutions across the U.S. and Canada. Through this expanded collaboration, IMCD will help enhance market reach, manage inventory more efficiently, and thus support medical device manufacturers with access to Lubrizol’s enhanced portfolio of medical-grade polymer technologies and development services.

APAC Market Insights

Asia Pacific medical polyurethane market is forecasted to grow at the fastest rate during the stipulated timeframe. The region’s upliftment is majorly propelled by massive government investments in healthcare infrastructure and a booming medical tourism sector. In addition, countries across the region are expanding their domestic medical device manufacturing capabilities, which increases the local consumption of high-purity polymers for producing medical consumables. For instance, in June 2025, Covestro began producing its Desmopan® Rx medical-grade TPU at its Changhua, Taiwan facility, expanding regional manufacturing capacity in Asia Pacific while ensuring compliance with international medical standards. This localized production will allow faster delivery, improved supply reliability, and support the growing demand for high-performance materials used in healthcare applications.

The government's focus on domesticating high-end medical device manufacturing and upgrading national healthcare infrastructure is positioning the medical polyurethane market in China for surging growth.  In addition, the country’s market progression is also being propelled by state initiatives that fund local biomaterial research and incentivize domestic firms to develop high-purity polyurethane formulations. In September 2024, Avient announced the expansion of NEUSoft™ TPU and NEU™ custom capabilities manufacturing to its Suzhou, China facility in order to strengthen support for healthcare and medical device customers across China and the Asia Pacific. Besides, this NEUSoft TPU portfolio is especially designed for short-term catheter applications and offers high flexibility, durability, UV stability, and compliance with recognized biocompatibility standards.

In India, the medical polyurethane market is projected to witness strategic growth, which is fueled by the expansion of domestic medical device manufacturing under national industrialization initiatives and substantial investments in private healthcare infrastructure. Besides, a rising middle-class population and the expanding coverage of public health insurance schemes are accelerating the clinical adoption of advanced medical care, including polyurethane-based wound dressings and diagnostic equipment. In this context, the Press Information Bureau (PIB) in December 2024 stated that the Production Linked Incentive (PLI) Scheme for medical devices was launched by the government to promote domestic manufacturing and reduce dependence on imported medical technologies, with a total financial outlay of USD 410 million. This particular scheme has supported 19 greenfield projects and enabled the production of 44 advanced medical devices, i.e., imaging systems, implants, stents, and catheters that were previously imported.

Europe Market Insights

In Europe, the medical polyurethane market is progressing at a steady pace, which is anchored by a mature healthcare ecosystem and a powerful emphasis on medical R&D. Market evolution in this region is highly sustained by deep academic-industrial collaborations, which are focused on developing innovative biomaterials, such as antimicrobial coatings and shape-memory polyurethanes.  For instance, Evonik in July 2025 entered into a partnership with IMCD to distribute RESOMER® bioresorbable medical device polymers across Europe, thereby expanding access to advanced biomaterials for implantable healthcare applications. This agreement will support the use of RESOMER® polymers in orthopedic devices, tissue reconstruction, dental meshes, and 3D-printed implantable devices through IMCD’s medical polymer expertise.

The nation’s well-established domestic medical technology sector and high healthcare standards are driving growth of the medical polyurethane market in Germany. The country’s market also benefits from a dense network of research institutes and chemical enterprises that are collaborating to pioneer advanced bio-stable formulations and custom surface coatings that minimize infection risks. For instance, in February 2026, Fraunhofer researchers developed a safer isocyanate-free polyurethane production process by using dicarbamates instead of toxic isocyanates. This approach efficiently improves worker safety, lowers emissions, and supports polyurethane recycling. Furthermore, Fraunhofer also mentions that this technology is being researched for medical catheter tubing and other high-performance applications.

The UK medical polyurethane market is growing steadily, which is supported by a strong domestic life sciences sector and continuous modernization efforts within the National Health Service (NHS).  Market growth is largely driven by close collaborations between leading British universities, clinical research networks, and medical device fabricators aimed at developing infection-resistant, bio-stable polymer formulations. In December 2024, the University of East Anglia stated that researchers developed an advanced polyurethane nanofiber wound dressing which is incorporated with heparin-coated silver nanoparticles, combining antimicrobial protection with properties that support faster wound healing. It mentions that this dressing demonstrated strong antibacterial activity against common wound pathogens, sustained silver release for up to seven days, moisture management, and good biocompatibility with skin cells.